@article{BarceloCoblijnLauraMartindeAlmeidaetal.2011, author = {Barcelo-Coblijn, Gwendolyn and Laura Martin, Maria and de Almeida, Rodrigo F. M. and Antonia Noguera-Salva, Maria and Marcilla-Etxenike, Amaia and Guardiola-Serrano, Francisca and Lueth, Anja and Kleuser, Burkhard and Halver, John E. and Escriba, Pablo V.}, title = {Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy}, series = {Proceedings of the National Academy of Sciences of the United States of America}, volume = {108}, journal = {Proceedings of the National Academy of Sciences of the United States of America}, number = {49}, publisher = {National Acad. of Sciences}, address = {Washington}, issn = {0027-8424}, doi = {10.1073/pnas.1115484108}, pages = {19569 -- 19574}, year = {2011}, abstract = {The mechanism of action of 2-hydroxyoleic acid (2OHOA), a potent antitumor compound, has not yet been fully elucidated. Here, we show that human cancer cells have markedly lower levels of sphingomyelin (SM) than nontumor (MRC-5) cells. In this context, 2OHOA treatment strongly augments SM mass (4.6-fold), restoring the levels found in MRC-5 cells, while a loss of phosphatidylethanolamine and phosphatidylcholine is observed (57 and 30\%, respectively). The increased SM mass was due to a rapid and highly specific activation of SM synthases (SMS). This effect appeared to be specific against cancer cells as it did not affect nontumor MRC-5 cells. Therefore, low SM levels are associated with the tumorigenic transformation that produces cancer cells. SM accumulation occurred at the plasma membrane and caused an increase in membrane global order and lipid raft packing in model membranes. These modifications would account for the observed alteration by 2OHOA in the localization of proteins involved in cell apoptosis (Fas receptor) or differentiation (Ras). Importantly, SMS inhibition by D609 diminished 2OHOA effect on cell cycle. Therefore, we propose that the regulation of SMS activity in tumor cells is a critical upstream event in 2OHOA antitumor mechanism, which also explains its specificity for cancer cells, its potency, and the lack of undesired side effects. Finally, the specific activation of SMS explains the ability of this compound to trigger cell cycle arrest, cell differentiation, and autophagy or apoptosis in cancer cells.}, language = {en} } @misc{BaeumerRossbachMischkeetal.2011, author = {B{\"a}umer, Wolfgang and Rossbach, Kristine and Mischke, Reinhard and Reines, Ilka and Langbein-Detsch, Ines and L{\"u}th, Anja and Kleuser, Burkhard}, title = {Decreased concentration and enhanced metabolism of sphingosine-1-Phosphate in lesional skin of dogs with atopic dermatitis disturbed Sphingosine-1-Phosphate homeostasis in atopic Dermatitis}, series = {The journal of investigative dermatology}, volume = {131}, journal = {The journal of investigative dermatology}, number = {1}, publisher = {Nature Publ. Group}, address = {New York}, issn = {0022-202X}, doi = {10.1038/jid.2010.252}, pages = {266 -- 268}, year = {2011}, language = {en} } @article{LuethNeuberKleuser2012, author = {L{\"u}th, Anja and Neuber, Corinna and Kleuser, Burkhard}, title = {Novel methods for the quantification of (2E)-hexadecenal by liquid chromatography with detection by either ESI QTOF tandem mass spectrometry or fluorescence measurement}, series = {Analytica chimica acta : an international journal devoted to all branches of analytical chemistry}, volume = {722}, journal = {Analytica chimica acta : an international journal devoted to all branches of analytical chemistry}, publisher = {Elsevier}, address = {Amsterdam}, issn = {0003-2670}, doi = {10.1016/j.aca.2012.01.063}, pages = {70 -- 79}, year = {2012}, abstract = {Sphingosine-1-phosphate lyase (SPL) is the only known enzyme that irreversibly cleaves sphingosine-1-phosphate (S1P) into phosphoethanolamine and (2E)-hexadecenal during the final step of sphingolipid catabolism. Because S1P is involved in a wide range of physiological and diseased processes, determining the activity of the degrading enzyme is of great interest. Therefore, we developed two procedures based on liquid chromatography (LC) for analysing (2E)-hexadecenal, which is one of the two S1P degradation products. After separation, two different quantification methods were performed, tandem mass spectrometry (MS) and fluorescence detection. However, (2E)-hexadecenal as a long-chain aldehyde is not ionisable by electrospray ionisation (ESI) for MS quantification and has an insufficient number of corresponding double bonds for fluorescence detection. Therefore, we investigated 2-diphenylacetyl-1,3-indandione-1-hydrazone (DAIH) as a derivatisation reagent. DAIH transforms the aldehyde into an ionisable and fluorescent analogue for quantitative analysis. Our conditions were optimised to obtain the outstanding limit of detection (LOD) of 1 fmol per sample (30 mu L) for LC-MS/MS and 0.75 pmol per sample (200 mu l) for LC determination with fluorescence detection. We developed an extraction procedure to separate and concentrate (2E)-hexadecenal from biological samples for these measurements. To confirm our new methods, we analysed the (2E)-hexadecenal level of different cell lines and human plasma for the first time ever. Furthermore, we treated HT-29 cells with different concentrations of 4-deoxypyridoxine (DOP), which competitively inhibits pyridoxal-5-phosphate (P5P), an essential cofactor for SPL activity, and observed a significant decrease in (2E)-hexadecenal relative to the untreated cells.}, language = {en} } @inproceedings{BoehmPolzinLuethetal.2012, author = {Boehm, Andreas and Polzin, A. and Lueth, Anja and Kleuser, Burkhard and Rassaf, T. and Kelm, M. and Kroemer, H. K. and Schroer, K. and Rauch, B. H.}, title = {The release of sphingosine-1-phosphate from human platelets during acute coronary syndrome is attenuated by aspirin}, series = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, volume = {385}, booktitle = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, publisher = {Springer}, address = {New York}, issn = {0028-1298}, pages = {12 -- 12}, year = {2012}, language = {en} } @inproceedings{SchaperKietzmannKleuseretal.2012, author = {Schaper, K. and Kietzmann, M. and Kleuser, Burkhard and Baeumer, W.}, title = {Effects of sphingosine-1-phosphate and FTY720 on epidermal hyperproliferation and inflammation in an imiquimod induced mouse model of psoriasis}, series = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, volume = {385}, booktitle = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, number = {3}, publisher = {Springer}, address = {New York}, issn = {0028-1298}, pages = {80 -- 80}, year = {2012}, language = {en} } @article{SchmitzPotteckSchueppeletal.2012, author = {Schmitz, Elisabeth I. and Potteck, Henrik and Sch{\"u}ppel, Melanie and Manggau, Marianti and Wahydin, Elly and Kleuser, Burkhard}, title = {Sphingosine 1-phosphate protects primary human keratinocytes from apoptosis via nitric oxide formation through the receptor subtype S1P(3)}, series = {Molecular and cellular biochemistry : an international journal for chemical biology in health and disease}, volume = {371}, journal = {Molecular and cellular biochemistry : an international journal for chemical biology in health and disease}, number = {1-2}, publisher = {Springer}, address = {Dordrecht}, issn = {0300-8177}, doi = {10.1007/s11010-012-1433-5}, pages = {165 -- 176}, year = {2012}, abstract = {Although the lipid mediator sphingosine 1-phosphate (S1P) has been identified to induce cell growth arrest of human keratinocytes, the sphingolipid effectively protects these epidermal cells from apoptosis. The molecular mechanism of the anti-apoptotic action induced by S1P is less characterized. Apart from S1P, endogenously produced nitric oxide (NOaEuro cent) has been recognized as a potent modulator of apoptosis in keratinocytes. Therefore, it was of great interest to elucidate whether S1P protects human keratinocytes via a NOaEuro cent-dependent signalling pathway. Indeed, S1P induced an activation of endothelial nitric oxide synthase (eNOS) in human keratinocytes leading to an enhanced formation of NOaEuro cent. Most interestingly, the cell protective effect of S1P was almost completely abolished in the presence of the eNOS inhibitor L-NAME as well as in eNOS-deficient keratinocytes indicating that the sphingolipid metabolite S1P protects human keratinocytes from apoptosis via eNOS activation and subsequent production of protective amounts of NOaEuro cent. It is well established that most of the known actions of S1P are mediated by a family of five specific G protein-coupled receptors. Therefore, the involvement of S1P-receptor subtypes in S1P-mediated eNOS activation has been examined. Indeed, this study clearly shows that the S1P(3) is the exclusive receptor subtype in human keratinocytes which mediates eNOS activation and NOaEuro cent formation in response to S1P. In congruence, when the S1P(3) receptor subtype is abrogated, S1P almost completely lost its ability to protect human keratinocytes from apoptosis.}, language = {en} } @inproceedings{NatekLuethKleuseretal.2012, author = {Natek, M. and L{\"u}th, Anja and Kleuser, Burkhard and Sch{\"a}fer-Korting, M. and Weindl, G.}, title = {CpG-oligonucleotides modulate sphingosine-1-phosphate metabolism in normal human keratinocytes}, series = {The journal of investigative dermatology}, volume = {132}, booktitle = {The journal of investigative dermatology}, number = {5}, publisher = {Nature Publ. Group}, address = {New York}, issn = {0022-202X}, pages = {S112 -- S112}, year = {2012}, language = {en} } @article{JaptokSchaperBaeumeretal.2012, author = {Japtok, Lukasz and Schaper, Katrin and B{\"a}umer, Wolfgang and Radeke, Heinfried H. and Jeong, Se Kyoo and Kleuser, Burkhard}, title = {Sphingosine 1-Phosphate Modulates Antigen Capture by Murine Langerhans Cells via the S1P(2) Receptor Subtype}, series = {PLOS ONE}, volume = {7}, journal = {PLOS ONE}, number = {11}, publisher = {PUBLIC LIBRARY SCIENCE}, address = {SAN FRANCISCO}, issn = {1932-6203}, doi = {10.1371/journal.pone.0049427}, pages = {11}, year = {2012}, abstract = {Dendritic cells (DCs) play a pivotal role in the development of cutaneous contact hypersensitivity (CHS) and atopic dermatitis as they capture and process antigen and present it to T lymphocytes in the lymphoid organs. Recently, it has been indicated that a topical application of the sphingolipid sphingosine 1-phosphate (S1P) prevents the inflammatory response in CHS, but the molecular mechanism is not fully elucidated. Here we indicate that treatment of mice with S1P is connected with an impaired antigen uptake by Langerhans cells (LCs), the initial step of CHS. Most of the known actions of S1P are mediated by a family of five specific G protein-coupled receptors. Our results indicate that S1P inhibits macropinocytosis of the murine LC line XS52 via S1P(2) receptor stimulation followed by a reduced phosphatidylinositol 3-kinase (PI3K) activity. As down-regulation of S1P(2) not only diminished S1P-mediated action but also enhanced the basal activity of LCs on antigen capture, an autocrine action of S1P has been assumed. Actually, S1P is continuously produced by LCs and secreted via the ATP binding cassette transporter ABCC1 to the extracellular environment. Consequently, inhibition of ABCC1, which decreased extracellular S1P levels, markedly increased the antigen uptake by LCs. Moreover, stimulation of sphingosine kinase activity, the crucial enzyme for S1P formation, is connected not only with enhanced S1P levels but also with diminished antigen capture. These results indicate that S1P is essential in LC homeostasis and influences skin immunity. This is of importance as previous reports suggested an alteration of S1P levels in atopic skin lesions. Citation: Japtok L, Schaper K, Baumer W, Radeke HH, Jeong SK, et al. (2012) Sphingosine 1-Phosphate Modulates Antigen Capture by Murine Langerhans Cells via the S1P(2) Receptor Subtype. PLoS ONE 7(11): e49427. doi:10.1371/journal.pone.0049427}, language = {en} } @article{GereckeMascherGottschalketal.2013, author = {Gerecke, Christian and Mascher, Conny and Gottschalk, Uwe and Kleuser, Burkhard and Scholtka, Bettina}, title = {Ultrasensitive detection of unknown colon cancer-initiating mutations using the example of the adenomatous polyposis coli gene}, series = {Cancer prevention research}, volume = {6}, journal = {Cancer prevention research}, number = {9}, publisher = {American Association for Cancer Research}, address = {Philadelphia}, issn = {1940-6207}, doi = {10.1158/1940-6207.CAPR-13-0145}, pages = {898 -- 907}, year = {2013}, abstract = {Detection of cancer precursors contributes to cancer prevention, for example, in the case of colorectal cancer. To record more patients early, ultrasensitive methods are required for the purpose of noninvasive precursor detection in body fluids. Our aim was to develop a method for enrichment and detection of known as well as unknown driver mutations in the Adenomatous polyposis coli (APC) gene. By coupled wild-type blocking (WTB) PCR and high-resolution melting (HRM), referred to as WTB-HRM, a minimum detection limit of 0.01\% mutant in excess wild-type was achieved according to as little as 1 pg mutated DNA in the assay. The technique was applied to 80 tissue samples from patients with colorectal cancer (n = 17), adenomas (n = 50), serrated lesions (n = 8), and normal mucosa (n = 5). Any kind of known and unknown APC mutations (deletions, insertions, and base exchanges) being situated inside the mutation cluster region was distinguishable from wild-type DNA. Furthermore, by WTB-HRM, nearly twice as many carcinomas and 1.5 times more precursor lesions were identified to be mutated in APC, as compared with direct sequencing. By analyzing 31 associated stool DNA specimens all but one of the APC mutations could be recovered. Transferability of the WTB-HRM method to other genes was proven using the example of KRAS mutation analysis. In summary, WTB-HRM is a new approach for ultrasensitive detection of cancer-initiating mutations. In this sense, it appears especially applicable for noninvasive detection of colon cancer precursors in body fluids with excess wild-type DNA like stool. Cancer Prev Res; 6(9); 898-907. (C) 2013 AACR.}, language = {en} } @article{LotinunKivirantaMatsubaraetal.2013, author = {Lotinun, Sutada and Kiviranta, Riku and Matsubara, Takuma and Alzate, Jorge A. and Neff, Lynn and L{\"u}th, Anja and Koskivirta, Ilpo and Kleuser, Burkhard and Vacher, Jean and Vuorio, Eero and Horne, William C. and Baron, Roland}, title = {Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation}, series = {The journal of clinical investigation}, volume = {123}, journal = {The journal of clinical investigation}, number = {2}, publisher = {American Society for Clinical Investigation}, address = {Ann Arbor}, issn = {0021-9738}, doi = {10.1172/JCI64840}, pages = {666 -- 681}, year = {2013}, abstract = {Cathepsin K (CTSK) is secreted by osteoclasts to degrade collagen and other matrix proteins during bone resorption. Global deletion of Ctsk in mice decreases bone resorption, leading to osteopetrosis, but also increases the bone formation rate (BFR). To understand how Ctsk deletion increases the BFR, we generated osteoclast- and osteoblast-targeted Ctsk knockout mice using floxed Ctsk alleles. Targeted ablation of Ctsk in hematopoietic cells, or specifically in osteoclasts and cells of the monocyte-osteoclast lineage, resulted in increased bone volume and BFR as well as osteoclast and osteoblast numbers. In contrast, targeted deletion of Ctsk in osteoblasts had no effect on bone resorption or BFR, demonstrating that the increased BFR is osteoclast dependent. Deletion of Ctsk in osteoclasts increased their sphingosine kinase 1 (Sphk1) expression. Conditioned media from Ctsk-deficient osteoclasts, which contained elevated levels of sphingosine-l-phosphate (S1P), increased alkaline phosphatase and mineralized nodules in osteoblast cultures. An S1P(1,3) receptor antagonist inhibited these responses. Osteoblasts derived from mice with Ctsk-deficient osteoclasts had an increased RANKL/OPG ratio, providing a positive feedback loop that increased the number of osteoclasts. Our data provide genetic evidence that deletion of CTSK in osteoclasts enhances bone formation in vivo by increasing the generation of osteoclast-derived S1P.}, language = {en} } @article{BhabakKleuserHuwileretal.2013, author = {Bhabak, Krishna P. and Kleuser, Burkhard and Huwiler, Andrea and Arenz, Christoph}, title = {Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues}, series = {Bioorganic \& medicinal chemistry : a Tetrahedron publication for the rapid dissemination of full original research papers and critical reviews on biomolecular chemistry, medicinal chemistry and related disciplines}, volume = {21}, journal = {Bioorganic \& medicinal chemistry : a Tetrahedron publication for the rapid dissemination of full original research papers and critical reviews on biomolecular chemistry, medicinal chemistry and related disciplines}, number = {4}, publisher = {Elsevier}, address = {Oxford}, issn = {0968-0896}, doi = {10.1016/j.bmc.2012.12.014}, pages = {874 -- 882}, year = {2013}, abstract = {Induction of apoptosis mediated by the inhibition of ceramidases has been shown to enhance the efficacy of conventional chemotherapy in several cancer models. Among the inhibitors of ceramidases reported in the literature, B-13 is considered as a lead compound having good in vitro potency towards acid ceramidase. Furthermore, owing to the poor activity of B-13 on lysosoamal acid ceramidase in living cells, LCL-464 a modified derivative of B-13 containing a basic omega-amino group at the fatty acid was reported to have higher potency towards lysosomal acid ceramidase in living cells. In a search for more potent inhibitors of ceramidases, we have designed a series of compounds with structural modifications of B-13 and LCL-464. In this study, we show that the efficacy of B-13 in vitro as well as in intact cells can be enhanced by suitable modification of functional groups. Furthermore, a detailed SAR investigation on LCL-464 analogues revealed novel promising inhibitors of aCDase and nCDase. In cell culture studies using the breast cancer cell line MDA-MB-231, some of the newly developed compounds elevated endogenous ceramide levels and in parallel, also induced apoptotic cell death. In summary, this study shows that structural modification of the known ceramidase inhibitors B-13 and LCL-464 generates more potent ceramidase inhibitors that are active in intact cells and not only elevates the cellular ceramide levels, but also enhances cell death.}, language = {en} } @misc{PolzinRassafBoehmetal.2013, author = {Polzin, Amin and Rassaf, Tienush and Boehm, Andreas and Lueth, Anja and Kleuser, Burkhard and Zeus, Tobias and Kelm, Malte and Kroemer, Heyo K. and Schroer, Karsten and Rauch, Bernhard H.}, title = {Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction}, series = {INTERNATIONAL JOURNAL OF CARDIOLOGY}, volume = {170}, journal = {INTERNATIONAL JOURNAL OF CARDIOLOGY}, number = {2}, publisher = {ELSEVIER IRELAND LTD}, address = {CLARE}, issn = {0167-5273}, doi = {10.1016/j.ijcard.2013.10.050}, pages = {E23 -- E24}, year = {2013}, language = {en} } @article{GulbinsPalmadaReicheletal.2013, author = {Gulbins, Erich and Palmada, Monica and Reichel, Martin and Lueth, Anja and Boehmer, Christoph and Amato, Davide and Mueller, Christian P. and Tischbirek, Carsten H. and Groemer, Teja W. and Tabatabai, Ghazaleh and Becker, Katrin Anne and Tripal, Philipp and Staedtler, Sven and Ackermann, Teresa F. and van Brederode, Johannes and Alzheimer, Christian and Weller, Michael and Lang, Undine E. and Kleuser, Burkhard and Grassme, Heike and Kornhuber, Johannes}, title = {Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs}, series = {Nature medicine}, volume = {19}, journal = {Nature medicine}, number = {7}, publisher = {Nature Publ. Group}, address = {New York}, issn = {1078-8956}, doi = {10.1038/nm.3214}, pages = {934 -- +}, year = {2013}, abstract = {Major depression is a highly prevalent severe mood disorder that is treated with antidepressants. The molecular targets of antidepressants require definition. We investigated the role of the acid sphingomyelinase (Asm)-ceramide system as a target for antidepressants. Therapeutic concentrations of the antidepressants amitriptyline and fluoxetine reduced Asm activity and ceramide concentrations in the hippocampus, increased neuronal proliferation, maturation and survival and improved behavior in mouse models of stress-induced depression. Genetic Asm deficiency abrogated these effects. Mice overexpressing Asm, heterozygous for acid ceramidase, treated with blockers of ceramide metabolism or directly injected with C16 ceramide in the hippocampus had higher ceramide concentrations and lower rates of neuronal proliferation, maturation and survival compared with controls and showed depression-like behavior even in the absence of stress. The decrease of ceramide abundance achieved by antidepressant-mediated inhibition of Asm normalized these effects. Lowering ceramide abundance may thus be a central goal for the future development of antidepressants.}, language = {en} } @article{BoehmFloesserErmleretal.2013, author = {B{\"o}hm, Andreas and Fl{\"o}ßer, Anja and Ermler, Swen and Fender, Anke C. and L{\"u}th, Anja and Kleuser, Burkhard and Schr{\"o}r, Karsten and Rauch, Bernhard H.}, title = {Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells}, series = {Cardiovascular research}, volume = {99}, journal = {Cardiovascular research}, number = {3}, publisher = {Oxford Univ. Press}, address = {Oxford}, issn = {0008-6363}, doi = {10.1093/cvr/cvt112}, pages = {505 -- 513}, year = {2013}, abstract = {Sphingosine-1-phosphate (S1P) is a cellular signalling lipid generated by sphingosine kinase-1 (SPHK1). The aim of the study was to investigate whether the activated coagulation factor-X (FXa) regulates SPHK1 transcription and the formation of S1P and subsequent mitogenesis and migration of human vascular smooth muscle cells (SMC). FXa induced a time- (36 h) and concentration-dependent (330 nmol/L) increase of SPHK1 mRNA and protein expression in human aortic SMC, resulting in an increased synthesis of S1P. FXa-stimulated transcription of SPHK1 was mediated by the protease-activated receptor-1 (PAR-1) and PAR-2. In human carotid artery plaques, expression of SPHK1 was observed at SMC-rich sites and was co-localized with intraplaque FX/FXa content. FXa-induced SPHK1 transcription was attenuated by inhibitors of Rho kinase (Y27632) and by protein kinase C (PKC) isoforms (GF109203X). In addition, FXa rapidly induced the activation of the small GTPase Rho A. Inhibition of signalling pathways which regulate SPHK1 expression, inhibition of its activity or siRNA-mediated SPHK1 knockdown attenuated the mitogenic and chemotactic response of human SMC to FXa. These data suggest that FXa induces SPHK1 expression and increases S1P formation independent of thrombin and that this involves the activation of Rho A and PKC signalling. In addition to its key function in coagulation, this direct effect of FXa on human SMC may increase cell proliferation and migration at sites of vessel injury and thereby contribute to the progression of vascular lesions.}, language = {en} } @article{SchaperDickhautJaptoketal.2013, author = {Schaper, Katrin and Dickhaut, Jeannette and Japtok, Lukasz and Kietzmann, Manfred and Mischke, Reinhard and Kleuser, Burkhard and B{\"a}umer, Wolfgang}, title = {Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis}, series = {Journal of dermatological scienc}, volume = {71}, journal = {Journal of dermatological scienc}, number = {1}, publisher = {Elsevier}, address = {Clare}, issn = {0923-1811}, doi = {10.1016/j.jdermsci.2013.03.006}, pages = {29 -- 36}, year = {2013}, abstract = {Background: It has been indicated that the sphingolipid sphingosine-1-phosphate (SIP) restrains the ability of dendritic cells to migrate to lymph nodes. Furthermore SIP has been demonstrated to inhibit cell growth in human keratinocytes. However, only little is known about the effect of S1P in hyperproliferative and inflammatory in vivo models. Objective: In this study, locally acting SIP was explored in different experimental mouse models of psoriasis vulgaris. Methods: S1P and FTY720 were tested in the imiquimod-induced psoriasis mouse model, the mouse tail assay and a pilot study of the severe combined immunodeficiency mice (SCID). Results: In the imiquimod model the positive control diflorasone diacetate and S1P, but not FTY720 reduced the imiquimod-induced epidermal hyperproliferation of the ear skin. This effect was confirmed in the SCID model, where S1P treated skin from patients suffering from psoriasis showed a decrease in epidermal thickness compared to vehicle. In the imiquimod model, there was also significant inhibition of ear swelling and a moderate reduction of inflammatory cell influx and oedema formation in ear skin by SIP treatment. The inflammatory response on the back skin was, however, only reduced by diflorasone diacetate. In the mouse tail assay, the influence of S1P and FTY720 in stratum granulosum formation was tested compared to the positive control calcipotriol. Whereas topical administration of calcipotriol led to a low but significant increase of stratum granulosum, S1P and FTY720 lacked such an effect. Conclusion: Taken together, these results imply that topical administration of SIP might be a new option for the treatment of mild to moderate psoriasis lesions.}, language = {en} } @article{PutraNeuberReichetzederetal.2014, author = {Putra, Sulistyo Emantoko Dwi and Neuber, Corinna and Reichetzeder, Christoph and Hocher, Berthold and Kleuser, Burkhard}, title = {Analysis of genomic DNA methylation levels in human placenta using liquid Chromatography-Electrospray ionization tandem mass spectrometry}, series = {Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry and pharmacology}, volume = {33}, journal = {Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry and pharmacology}, number = {4}, publisher = {Karger}, address = {Basel}, issn = {1015-8987}, doi = {10.1159/000358666}, pages = {945 -- 952}, year = {2014}, abstract = {Background: DNA-methylation is a common epigenetic tool which plays a crucial role in gene regulation and is essential for cell differentiation and embryonic development. The placenta is an important organ where gene activity can be regulated by epigenetic DNA modifications, including DNA methylation. This is of interest as, the placenta is the interface between the fetus and its environment, the mother. Exposure to environmental toxins and nutrition during pregnancy may alter DNA methylation of the placenta and subsequently placental function and as a result the phenotype of the offspring. The aim of this study was to develop a reliable method to quantify DNA methylation in large clinical studies. This will be a tool to analyze the degree of DNA methylation in the human placenta in relationship to clinical readouts. Methods: Liquid chromatography-electrospray ionization/multi-stage mass spectrometry (LC-ESI/MS/MS) technique was used for the quantification of the 5dmC/dG ratio in placentas from 248 healthy pregnancies. We were able to demonstrate that this method is a reliable and stable way to determine global placental DNA methylation in large clinical trials. Results/Conclusion: The degree of placental DNA methylation seen in our pilot study varies substantially from 2\% to 5\%. The clinical implications of this variation need to be demonstrated in adequately powered large studies.}, language = {en} } @inproceedings{ArltSchwiebsPfarretal.2014, author = {Arlt, Olga and Schwiebs, Anja and Pfarr, Kathrin and Ranglack, Annika and Bouzas, Ferreiros Nerea and Schreiber, Yannick and Neuber, Corinna and Kleuser, Burkhard and Pfeilschifter, Josef M. and Radeke, Heinfried H.}, title = {Dynamic interaction between sphingolipid enzymes, S1P and inflammatory cytokine regulation in dendritic cells}, series = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, volume = {387}, booktitle = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, publisher = {Springer}, address = {New York}, issn = {0028-1298}, pages = {S91 -- S91}, year = {2014}, language = {en} } @article{ImeriFalleggerZivkovicetal.2014, author = {Imeri, Faik and Fallegger, Daniel and Zivkovic, Aleksandra and Schwalm, Stephanie and Enzmann, Gaby and Blankenbach, Kira and Heringdorf, Dagmar Meyer Zu and Homann, Thomas and Kleuser, Burkhard and Pfeilschifter, Josef and Engelhardt, Britta and Stark, Holger and Huwiler, Andrea}, title = {Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice}, series = {Neuropharmacology}, volume = {85}, journal = {Neuropharmacology}, publisher = {Elsevier}, address = {Oxford}, issn = {0028-3908}, doi = {10.1016/j.neuropharm.2014.05.012}, pages = {314 -- 327}, year = {2014}, abstract = {The immunomodulatory FTY720 (fingolimod) is presently approved for the treatment of relapsing-remitting multiple sclerosis. It is a prodrug that acts by modulating sphingosine 1-phosphate (S1P) receptor signaling. In this study, we have developed and characterized two novel oxazolo-oxazole derivatives of FTY720, ST-968 and the oxy analog ST-1071, which require no preceding activating phosphorylation, and proved to be active in intact cells and triggered S1P(1) and S1P(3), but not S1P(2), receptor internalization as a result of receptor activation. Functionally, ST-968 and ST-1071 acted similar to FTY720 to abrogate S1P-triggered chemotaxis of mouse splenocytes, mouse T cells and human U937 cells, and reduced TNFa- and LPS-stimulated endothelial cell permeability. The compounds also reduced TNF alpha-induced ICAM-1 and VCAM-1 mRNA expression, but restored TNF alpha-mediated downregulation of PECAM-1 mRNA expression. In an in vivo setting, the application of ST-968 or ST-1071 to mice resulted in a reduction of blood lymphocytes and significantly reduced the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice comparable to FTY720 either by prophylactic or therapeutic treatment. In parallel to the reduced clinical symptoms, infiltration of immune cells in the brain was strongly reduced, and in isolated tissues of brain and spinal cord, the mRNA and protein expressions of ICAM-1 and VCAM-1, as well as of matrix metalloproteinase-9 were reduced by all compounds, whereas PECAM-1 and tissue inhibitor of metalloproteinase TIMP-1 were upregulated. In summary, the data suggest that these novel butterfly derivatives of FTY720 could have considerable implication for future therapies of multiple sclerosis and other autoimmune diseases. (C) 2014 Elsevier Ltd. All rights reserved.}, language = {en} } @article{KellerCatalaLehnenHuebneretal.2014, author = {Keller, Johannes and Catala-Lehnen, Philip and Huebner, Antje K. and Jeschke, Anke and Heckt, Timo and Lueth, Anja and Krause, Matthias and Koehne, Till and Albers, Joachim and Schulze, Jochen and Schilling, Sarah and Haberland, Michael and Denninger, Hannah and Neven, Mona and Hermans-Borgmeyer, Irm and Streichert, Thomas and Breer, Stefan and Barvencik, Florian and Levkau, Bodo and Rathkolb, Birgit and Wolf, Eckhard and Calzada-Wack, Julia and Neff, Frauke and Gailus-Durner, Valerie and Fuchs, Helmut and de Angelis, Martin Hrabe and Klutmann, Susanne and Tsourdi, Elena and Hofbauer, Lorenz C. and Kleuser, Burkhard and Chun, Jerold and Schinke, Thorsten and Amling, Michael}, title = {Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts}, series = {Nature Communications}, volume = {5}, journal = {Nature Communications}, publisher = {Nature Publ. Group}, address = {London}, issn = {2041-1723}, doi = {10.1038/ncomms6215}, pages = {13}, year = {2014}, abstract = {The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about the underlying cellular and molecular mechanism of CT action. Here we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of Spns2 gene, which encodes a transporter for the signalling lipid sphingosine 1-phosphate (S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is normalized by deletion of the S1P receptor S1P(3). Finally, pharmacologic treatment with the nonselective S1P receptor agonist FTY720 causes increased bone formation in wild-type, but not in S1P(3)-deficient mice. This study redefines the role of CT in skeletal biology, confirms that S1P acts as an osteoanabolic molecule in vivo and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts.}, language = {en} } @inproceedings{BaranyaiGoedtelArmbrustNestleretal.2014, author = {Baranyai, Dorothea and Goedtel-Armbrust, Ute and Nestler, Sebastian and Kleuser, Burkhard and Wojnowski, Leszek}, title = {A role for cutaneous CYP3A in vitamin D homeostasis?}, series = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, volume = {387}, booktitle = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY}, publisher = {Springer}, address = {New York}, issn = {0028-1298}, pages = {S27 -- S27}, year = {2014}, language = {en} }